|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,860.00 KRW | +0.21% |
|
-8.82% | -28.74% |
| Dec. 09 | GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy | CI |
| 25-06-12 | GC Genome Shares Decline Nearly 3% After Strong Kosdaq Debut | MT |
Projected Income Statement: GC Genome Corporation
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Net sales 1 | - | - | 39 | 48.8 |
| Change | - | - | - | 25.13% |
| EBITDA | - | - | - | - |
| Change | - | - | - | - |
| EBIT 1 | - | - | 4 | 7 |
| Change | - | - | - | 75% |
| Interest Paid | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - |
| Change | - | - | - | - |
| Net income | -1.257 | 4.044 | - | - |
| Change | - | 421.77% | - | - |
| Announcement Date | 4/4/25 | 3/16/26 | - | - |
1KRW in Billions
Estimates
Forecast Balance Sheet: GC Genome Corporation
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Net Debt 1 | - | - | -59.4 | -68.8 |
| Change | - | - | - | -15.82% |
| Announcement Date | 4/4/25 | 3/16/26 | - | - |
1KRW in Billions
Estimates
Cash Flow Forecast: GC Genome Corporation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| CAPEX 1 | 2,416 | 2,868 | 4,029 | 7,406 | 328.6 | 311.4 |
| Change | - | 18.68% | 40.49% | 83.82% | -95.56% | -5.24% |
| Free Cash Flow (FCF) 1 | -2,369 | -3,846 | -933.3 | -7,596 | -3,001 | -1,055 |
| Change | - | -62.31% | 75.73% | -713.88% | 60.49% | 64.85% |
| Announcement Date | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 | 3/1/25 | 3/1/26 |
1KRW in Million
Estimates
Forecast Financial Ratios: GC Genome Corporation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | - | - | - | - | - | - | - | - |
| EBIT Margin (%) | - | - | - | - | - | - | 10.26% | 14.34% |
| EBT Margin (%) | - | - | - | - | - | - | - | - |
| Net margin (%) | - | - | - | - | - | - | - | - |
| FCF margin (%) | - | - | - | - | - | - | - | - |
| FCF / Net Income (%) | - | - | - | - | - | - | - | - |
Profitability | ||||||||
| ROA | - | - | - | - | - | - | - | - |
| ROE | - | - | - | - | - | - | 6.9% | 8.9% |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Debt / Free cash flow | - | - | - | - | - | - | - | - |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | - | - | - | - | - | - | - | - |
| CAPEX / EBITDA (%) | - | - | - | - | - | - | - | - |
| CAPEX / FCF (%) | - | - | - | - | - | - | - | - |
Items per share | ||||||||
| Cash flow per share 1 | 528 | 671.6 | 844 | 198.3 | 358.3 | 1,485 | - | - |
| Change | - | 27.19% | 25.67% | -76.5% | 80.67% | 314.37% | - | - |
| Dividend per Share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Book Value Per Share 1 | 1,047 | 1,186 | 1,645 | 1,366 | 1,816 | 3,310 | - | - |
| Change | - | 13.22% | 38.76% | -16.98% | 32.94% | 82.25% | - | - |
| EPS 1 | -0.15 | 18.33 | -232.9 | -30 | -69 | 184.6 | - | - |
| Change | - | 12,320% | -1,370.59% | 87.12% | -130% | 367.5% | - | - |
| Nbr of stocks (in thousands) | - | - | - | - | - | 23,651 | - | - |
| Announcement Date | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 | 3/1/25 | 3/1/26 | - | - |
1KRW
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E | - | - |
| PBR | - | - |
| EV / Sales | 1.42x | 0.95x |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Annual profits - Rate of surprise
- Stock Market
- Stocks
- A340450 Stock
- Financials GC Genome Corporation
Select your edition
All financial news and data tailored to specific country editions
